Literature DB >> 18207237

Early diagnosis followed by front-line autologous peripheral blood stem cell transplantation for patients affected by POEMS syndrome.

Luca Laurenti1, Silvia De Matteis, Mario Sabatelli, Amelia Conte, Patrizia Chiusolo, Federica Sorà, Nicola Piccirillo, Tommaso Za, Michela Tarnani, Elena Rossi, Giuseppe Leone, Simona Sica.   

Abstract

The acronym POEMS refers to polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes. This disease is progressive and weakening for patients and lead to death generally for neurological problem without therapy. We treated four patients affected by POEMS syndrome with front-line chemotherapy and autologous peripheral blood stem cell transplantation (aPBSCT). After a median follow-up of 40.5 months (range 12-52), all patients are alive with slow but progressive improvement in neurological disease, skin changes, performance status and without evidence of clonal plasmacytosis and organomegaly. In conclusion early diagnosis is crucial to obtain best response and improve clinical outcome.

Entities:  

Mesh:

Year:  2008        PMID: 18207237     DOI: 10.1016/j.leukres.2007.11.029

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

Review 1.  How I treat POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

2.  Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience.

Authors:  Il-Young Jang; Dok Hyun Yoon; Shin Kim; Kyoungmin Lee; Kwang-Kuk Kim; Young-Min Lim; Won-Ki Min; Cheolwon Suh
Journal:  Blood Res       Date:  2014-03-24

3.  VEGF and IL-6 Correlation in POEMS: a Potential Upcoming Marker of Active Disease and Early Autologous BMT Response.

Authors:  Annamaria Tomasso; Idanna Innocenti; Francesco Autore; Alberto Fresa; Giulia Benintende; Florenzia Vuono; Silvia Baroni; Claudia Giannotta; Patrizia Chiusolo; Federica Sorà; Simona Sica; Luca Laurenti
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-01-01       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.